IndexIQ Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

IndexIQ Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$379K	Buy	+14,134	New	+$475K	0.01%	905

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

IndexIQ Advisors's TPTX Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022: 14,134 shares worth $379K. The stake represents 0.01% of the portfolio and ranks #905 among its holdings.

155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

IndexIQ Advisors held 14,134 shares of Turning Point Therapeutics, Inc. Common Stock worth $379K as of Q1 2022.
Turning Point Therapeutics, Inc. Common Stock was a new IndexIQ Advisors position in Q1 2022.
Turning Point Therapeutics, Inc. Common Stock made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #905 holding.
155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.